A University of Virginia study reported mechanistic data in mice suggesting next-generation oral small-molecule GLP-1 receptor agonists suppress hedonic eating through reward circuits deeper in the brain than previously recognized. The findings were published in Nature and focused on orforglipron and danuglipron, including NIH-supported work tied to mechanistic understanding. The researchers used gene editing to render GLP-1 receptors more humanlike in mice, then tracked brain-region activation after dosing. In addition to pathways linked to appetite control, the study reported drug-evoked activity in the central amygdala, a brain region associated with desire. The work adds a neural circuitry layer to the ongoing market shift toward oral GLP-1s—an area where patient uptake is increasing and companies are competing on both clinical outcomes and differentiating mechanisms.